Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

Footnotes

• Number 5 in the series “Innovations in asthma and its treatment” Edited by P. O'Byrne and I. Pavord

• Previous articles in this series: No. 1: Asher MI, García-Marcos L, Pearce NE, et al. Trends in worldwide asthma prevalence. Eur Respir J 2020; 56: 2002094. No. 2: Hinks TSC, Levine SJ, Brusselle GG. Treatment options in type-2 low asthma. Eur Respir J 2021; 57: 2000528. No. 3: O'Byrne PM, Reddel HK, Beasley R. The management of mild asthma. Eur Respir J 2021; 57: 2003051. No. 4: Pijnenburg MW, Frey U, De Jongste JC, et al. Childhood asthma: pathogenesis and phenotypes. Eur Respir J 2022; 59: 2100731.

• Conflict of interest: C.J. Corrigan, J.P.T. Ward and D. Riccardi hold a patent for the development of calcium receptor antagonists for the treatment of inflammatory lung disease (https://patents.google.com/patent/WO2014049351A1/en), and D. Riccardi and P.L. Yarova have a pending Composition of Matter patent currently undergoing filing for development of new chemical entities: “Novel calcilytics for pulmonary disease” (IP from NCE GB1719023.2). These authors and the remaining authors L.J. Janssen, T.H. Lee and S. Ying declare no other conflicts of interest relevant to the content of this manuscript, including grants or contracts from any other entity, royalties or licences, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, support for attending meetings and/or travel, participation on a data safety monitoring board or advisory board, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, stock or stock options, receipt of equipment, materials, drugs, medical writing, gifts or other services or other financial or nonfinancial interests.

• Support statement: Some of the research by the authors cited in this article was supported by an Initial Foundation grant “Polycations and the calcium-sensing receptor (CaSR) in asthma” from Asthma UK awarded to C.J. Corrigan, J.P.T. Ward, P.J. Kemp and D. Riccardi, grants “Multifaceted CaSR” and “Biomedicine” awarded to P.J. Kemp and D. Riccardi from the Marie Curie Integrated Training Network, a KESS 2 Studentship awarded to D. Riccardi, and a Wellcome Trust Fellowship awarded to P.L. Yarova. Funding information for this article has been deposited with the Crossref Funder Registry.